Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
PRINCETON, N.J., Aug. 16, 2017 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO will present at the Liolios 6th Annual Gateway Conference on Thursday, September 7, 2017 at 8:00 AM PT in San Francisco, California.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. Follow Agile on social media: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.
About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.
Contact: Mary Coleman Investor Relations Agile Therapeutics, Inc. 609-683-1880
